Blood Test Can Predict Breast Cancer Risk
|
By LabMedica International staff writers Posted on 17 May 2012 |
|
A blood test that spots changes in a specific gene could reveal a woman's risk for breast cancer years before the disease has a chance to develop.
Women with the highest level of methylation on one area gene were more likely to develop cancer than those with the lowest level of methylation because high levels of methylation signal high levels of DNA flaws.
Scientists from Imperial College (London, UK) analyzed blood samples from breast cancer patients and women without breast cancer. The samples from the breast cancer patients were collected an average of three years before they were diagnosed with the disease. Samples were from a case-control study derived from a cohort of high-risk breast cancer families and nested case-control studies in two prospective cohorts. Bisulfite pyrosequencing was used to quantify methylation from 640 incident cases of invasive breast cancer and 741 controls.
The objective was to find out if the alteration of ataxia telangiectasia mutated (ATM) genes by a process called methylation could predict a woman's breast cancer risk. The analysis of the blood samples identified alterations in the ATM gene that did not occur because of having active cancer or cancer treatments. This result was particularly pronounced in blood samples taken from women under the age of 60.
This blood test used in combination with other breast cancer risk assessment tools such as genetic testing and risk factor profiling, could help identify women at higher risk. This early warning could be used to monitor these patients and one day perhaps even prevent them from developing breast cancer. The study identifies a significant association between breast cancer risk and gene-specific methylation in leucocyte DNA measured in prediagnostic blood samples from cases in prospective cohorts and using pyrosequencing, which is a highly quantitative method.
James Flanagan, PhD, the senior author of the study said, "We know that genetic variation contributes to a person's risk of disease. With this new study, we can now also say that epigenetic variation, or differences in how genes are modified, also has a role. So far, we have found alterations in one small region of a gene that appear to associate with risk of disease, and so the next step with this epigenetic research is a genome-wide approach to try and find all the associated genes" The study was published on May 1, 2012, in the journal Cancer Research.
Related Links:
Imperial College
Women with the highest level of methylation on one area gene were more likely to develop cancer than those with the lowest level of methylation because high levels of methylation signal high levels of DNA flaws.
Scientists from Imperial College (London, UK) analyzed blood samples from breast cancer patients and women without breast cancer. The samples from the breast cancer patients were collected an average of three years before they were diagnosed with the disease. Samples were from a case-control study derived from a cohort of high-risk breast cancer families and nested case-control studies in two prospective cohorts. Bisulfite pyrosequencing was used to quantify methylation from 640 incident cases of invasive breast cancer and 741 controls.
The objective was to find out if the alteration of ataxia telangiectasia mutated (ATM) genes by a process called methylation could predict a woman's breast cancer risk. The analysis of the blood samples identified alterations in the ATM gene that did not occur because of having active cancer or cancer treatments. This result was particularly pronounced in blood samples taken from women under the age of 60.
This blood test used in combination with other breast cancer risk assessment tools such as genetic testing and risk factor profiling, could help identify women at higher risk. This early warning could be used to monitor these patients and one day perhaps even prevent them from developing breast cancer. The study identifies a significant association between breast cancer risk and gene-specific methylation in leucocyte DNA measured in prediagnostic blood samples from cases in prospective cohorts and using pyrosequencing, which is a highly quantitative method.
James Flanagan, PhD, the senior author of the study said, "We know that genetic variation contributes to a person's risk of disease. With this new study, we can now also say that epigenetic variation, or differences in how genes are modified, also has a role. So far, we have found alterations in one small region of a gene that appear to associate with risk of disease, and so the next step with this epigenetic research is a genome-wide approach to try and find all the associated genes" The study was published on May 1, 2012, in the journal Cancer Research.
Related Links:
Imperial College
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Latest Technology News
- New Diagnostic System Achieves PCR Testing Accuracy
- DNA Biosensor Enables Early Diagnosis of Cervical Cancer
- Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
- Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
- First of Its Kind Technology Detects Glucose in Human Saliva
- Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop
- Novel Noninvasive Test Detects Malaria Infection without Blood Sample
- Portable Optofluidic Sensing Devices Could Simultaneously Perform Variety of Medical Tests
- Point-of-Care Software Solution Helps Manage Disparate POCT Scenarios across Patient Testing Locations
- Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents
- Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers
- Rapid POC Sensing Kit to Determine Gut Health from Blood Serum and Stool Samples
- Device Converts Smartphone into Fluorescence Microscope for Just USD 50
- Wi-Fi Enabled Handheld Tube Reader Designed for Easy Portability
Channels
Clinical Chemistry
view channel
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more
Molecular Diagnostics
view channel
Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
Two studies have identified proteins in the blood that could potentially alert individuals to the presence of cancer more than seven years before the disease is clinically diagnosed. Researchers found... Read more (1)_1.jpg "Image: Ultrasound image of micro-histotripsy liberation of biomarkers in a tumor (Photo courtesy of Joy Wang and Pradyumna Kedarisetti)"){kind=small}
Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
Ultrasound imaging serves as a noninvasive method to locate and monitor cancerous tumors effectively. However, crucial details about the cancer, such as the specific types of cells and genetic mutations... Read more_1.jpg "Image: The innovative method to customize and strengthen DNA origami structure promises breakthroughs in medicine (Photo courtesy of Shutterstock)")
.jpg "Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)")
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read moreMicrobiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
Rapid and accurate intraoperative diagnosis is essential for tumor surgery as it guides surgical decisions with precision. Traditional intraoperative assessments, such as frozen sections based on H&E... Read more
HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
Annually, over 604,000 women across the world are diagnosed with cervical cancer, and about 342,000 die from this disease, which is preventable and primarily caused by the Human Papillomavirus (HPV).... Read more
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue.... Read more
Industry
view channel
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
